TABLE 1.
Clinical and epidemiological data and antimicrobial susceptibility profile of A. baumannii clinical isolates included in the study.
| Isolate | Hospital | State | Collection Date | Clinical Sample | PFGE | ST (Pas/Ox) | MIC (μ g/mL)a |
|||||||||||
| SAMb | CAZb | FEPb | IPM | MEM | GEN | AMK | CIP | MINb | TGCb | PMBc | CSTc | |||||||
| 52944 | A | SP | Apr/13/2012 | Blood | 1A | 79/233 | >256/4 | >128 | 128 | 128 | 256 | 8 | 512 | >64 | 2 | 16 | 64 | 128 |
| 61317 | B | SP | Apr/11/2014 | Urine | 1B | 79/227 | 256/4 | >128 | 128 | 64 | 64 | >128 | 256 | >64 | 0.5 | 8 | 64 | >128 |
| 61979 | B | SP | May/29/2014 | Tracheal aspirate | 1B | 79/227 | 128/4 | >128 | 128 | 64 | 64 | >128 | 128 | >64 | 0.5 | 8 | 64 | >128 |
| 63231 | B | SP | Aug/30/2014 | Blood | 1C | 79/227 | >256/4 | >128 | 64 | 128 | 256 | >128 | 64 | >64 | ≤0.25 | 0.5 | 1 | 1 |
| 63485 | B | SP | Sep/14/2014 | Blood | 1C | 79/227 | >256/4 | >128 | 64 | 128 | 128 | >128 | 64 | >64 | ≤0.25 | 0.5 | 1 | 1 |
| 66116 | B | SP | Mar/25/2015 | Tracheal aspirate | 2A | 79/233 | ≤0.5/4 | >128 | 128 | 128 | 128 | 4 | 64 | >64 | ≤0.25 | 4 | 16 | 64 |
| 67098 | B | SP | May/25/2015 | Blood | 2B | 79/233 | >256/4 | >128 | 32 | 128 | 256 | 8 | 64 | >64 | 0.5 | 0.5 | 1 | 1 |
| 67510 | B | SP | Jun/22/2015 | Tracheal aspirate | 1B | 79/227 | 256/4 | >128 | 256 | 64 | 64 | >128 | 128 | >64 | 0.5 | 8 | 64 | >128 |
| 67745 | B | SP | Jul/14/2015 | Blood | 2C | 79/233 | >256/4 | >128 | 128 | 128 | 256 | 16 | 64 | >64 | 0.5 | 1 | 1 | 1 |
| 20189365 | C | SP | Jun/03/2017 | Tracheal aspirate | 2D | 79/233 | ≤0.5/4 | >128 | 64 | 128 | 64 | 4 | 128 | >64 | 1 | 8 | 4 | 16 |
| 20216722 | B | SP | Jun/09/2017 | Tracheal aspirate | 2D | 79/233 | ≤0.5/4 | >128 | 128 | 256 | 256 | 8 | 128 | >64 | 0.5 | 4 | 8 | 16 |
| 182122 | D | SP | Jun/19/2017 | CSF | 3 | 15/2141 | ≤0.5/4 | 8 | 64 | 128 | 32 | ≤0.5 | 16 | >64 | 0.5 | 16 | 32 | >128 |
| 71838 | B | SP | Jul/05/2017 | Blood | 4A | 15/236 | >256/4 | >128 | 64 | 128 | 128 | 2 | 32 | 32 | ≤0.25 | 0.5 | ≤0.25 | ≤0.25 |
| 206182 | D | SP | Jul/10/2017 | Ascitic fluid | 2E | 730/227 | 256/4 | 128 | >256 | >256 | 256 | >128 | 256 | >64 | 1 | 16 | 8 | 16 |
| 71813 | B | SP | Jul/14/2017 | Blood | 4B | 15/236 | >256/4 | >128 | 128 | 256 | 256 | 4 | 64 | >64 | ≤0.25 | 0.5 | ≤0.25 | ≤0.25 |
| 278860 | D | SP | Sep/11/2017 | Blood | 2F | 79/233 | >256/4 | >128 | >256 | >256 | 128 | 4 | 128 | >64 | 1 | 8 | 64 | >128 |
| 300736 | D | SP | Sep/28/2017 | BAL | 2F | 79/233 | >256/4 | >128 | >256 | >256 | 128 | 16 | 128 | >64 | 1 | 16 | 16 | 64 |
| 10042 | E | ES | Oct/06/2017 | Catheter blood | 4C | 15/236 | >256/4 | >128 | 128 | 64 | 128 | >128 | 64 | >64 | 0.5 | 4 | 64 | >128 |
AMK, amikacin; BAL, bronchoalveolar lavage; CAZ, ceftazidime; CIP, ciprofloxacin; CSF, cerebrospinal fluid; CST, colistin; ES, Espírito Santo; FEP, cefepime; GEN, gentamicin; IPM, imipenem; MEM, meropenem; MIC, minimal inhibitory concentration; MIN, minocycline; Ox, Oxford scheme; Pas, Pasteur scheme; PFGE, pulsed field gel electrophoresis; PMB, polymyxin B; SAM, ampicillin/sulbactam; SP, São Paulo; ST, sequence type; TGC, tigecycline. aIn vitro susceptibility according to BrCAST/EUCAST clinical breakpoints are highlighted in the gray boxes. bClinical breakpoints not established by BrCAST/EUCAST. cBrCAST provided breakpoints for both polymyxins, while EUCAST provided only for colistin.